CIRM Board Member, Jeff Sheehy, has a wonderful piece in Nature Medicine on why patient advocates play a critical role in decision making on research priorities (hat tip to Amy Adams who first blogged on Sheehy’s piece). Patient advocates bring a unique and valuable perspective to the table. Their role in guiding CIRM research funding […]
Why scientists must be advocates too: Jeff Sheehy Read More »
The Obama administration has announced it will “quickly” appeal the ES cell decision, but I’m not hearing anything about a stay on the judge’s order in the meantime or anything like that. It’s quite the opposite. The NIH, in the form of Director Francis Collins, has finally spoken about the federal judge’s ruling that apparently banned
Grim reality of the impact of judge’s ES cell decision is emerging Read More »
UPDATE: A second recent study, this one in Nature Genetics has found a novel genetic link between the immune system and Parkinson’s Disease. The authors were screening for genomic variants unique to Parkinson’s patients, finding known ones but also a novel linkage. The link was with the HLA region, known to play a key role
Parkinson’s Disease, promising new results on iPS cells Read More »
Regenerative medicine is very exciting. But what’s even better than regenerative medicine? Preventative medicine. If one can prevent a problem for occurring in the first place, it is far better than trying to treat it after the fact. Of course in many cases we do not know the causes of diseases so it is difficult
Update in 2020: It seems now after all these years that the consensus in the now more mature field is that IPSCs and ESCs are nearly identical in most cases, and both have some of the same translational challenges such as teratoma-forming activity. It’s interesting to read this post from nearly 10 years ago and
iPS cells coming into focus: not quite so similar to ESC after all Read More »